Liver toxicity encountered in the Veterans Administration trial of disulfiram in alcoholics.
Alcoholic subjects (453) were randomly assigned to disulfiram or placebo therapy and followed for up to 12 months for drinking. Drinking status was determined from interviews of the subject and a household contact each 2 months and from the analysis of eight blood samples or 39 urines submitted at intervals during the year. Liver status was monitored each 2 months by obtaining serum alkaline phosphatase, bilirubin, and AST. Sensitive criteria were arbitrarily selected to identify about 1/5 of the patients with episodic elevations of liver tests. There was no relationship of liver test elevations to disulfiram treatment. However, the elevated AST related significantly to drinking status (p = 0.004) as did elevated bilirubin (p = 0.044), but not elevated alkaline phosphatase (p = 0.146). Two hundred one patients had liver test elevations at least one time and were continued on drug, four were dropped. One hundred seventy-nine of these patients were drinking, 22 were abstinent, and four were indeterminant. It is concluded that patients on disulfiram with minor liver test abnormalities are usually drinking.
Iber
F L
FL
Lee
K
K
Lacoursiere
R
R
Fuller
R
R
D000437:Alcoholism / Q000534:rehabilitation*; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004221:Disulfiram / Q000009:adverse effects* / Q000627:therapeutic use; D004285:Dogs; D006519:Hepatitis, Alcoholic / Q000209:etiology; D006787:Hospitals, Veterans; D006801:Humans; D008111:Liver Function Tests
D004221:Disulfiram